Author: admin

The new entity will hold MinRes’ 50% ownership in the Wodgina and Mt Marion lithium mines, giving POSCO an indirect 15% interest in each of the projects.

Sign up here.

MinRes will remain the mines’ operator under its existing agreements with the respective partners.

POSCO will receive spodumene concentrate in proportion to its 30% interest, supporting its plans for new downstream processing facilities.

MinRes said the partnership builds on their existing Onslow Iron JV and will help meet rising demand for Australian lithium.

The deal, approved by both boards, is subject to regulatory clearances including Australia’s Foreign Investment Review Board.

Our Standards: The Thomson Reuters Trust Principles., opens new tab

When imatinib (Gleevec; Novartis), the first-ever tyrosine kinase inhibitor, made its debut in chronic myelogenous leukemia (CML), it revolutionized the treatment of a disease with a once-dismal prognosis.¹

Prior to its 2001 approval, CML therapies were often harsh, invasive, and ineffective.¹ Now, 25 years later, current studies continue to align with previous research associating imatinib with major cytogenic responses,² and targeted therapies have become cornerstones of treatment in a range of tumor types.³

Imatinib was first used to treat patients during a clinical trial in 1998. Lead researchers in the earliest studies were Brian J. Druker, MD; Stephen G. O’Brien, MD; Jorge Cortes, MD; and Jerald Radich, MD. The American Journal of Managed Care^® had the pleasure of speaking with Cortes, discussing the history and evolution of imatinib in the CML treatment paradigm.

Patients with CML, unlike patients with acute lymphoblastic leukemia, are likely to have a longer life expectancy with and without treatment. Those with CML can still have a life expectancy of 3 to 5 years after diagnosis without treatment, but with treatment, their life expectancy is closer to the national average.⁴

“I still remember Dr. Talpaz coming out of rooms and saying, ‘Wow, this thing works.’ He had this expression of wonder at the big change that it was representing… When the new study started…patients came to the study, but they wanted to get imatinib,” Cortes said.

Development of imatinib began in the early 1990s under Druker at Oregon Health and Science University.¹ Druker aimed to find a treatment for CML, and with the help of Nicholas Lyndon, MD, they identified a drug that was able to kill CML cells efficiently.¹

The phase 1 clinical trial of imatinib in 1998 was partially funded by the National Cancer Institute. The drug was then FDA-approved in 2001 to treat patients with CML. Of the patients in the original trial, 5 years later, 98% of them were still in remission.

“[But] we’re not done [yet]. Patients are still looking for a better quality of life, for being able to stop therapy and all of that. We’ve made tremendous progress, and… we want to be optimistic, but we want to still always be careful and cautious and respect what cancer can do,” Cortes said.

Listen above or on one of these podcast services:

iTunes
TuneIn
Stitcher
Spotify

References

1. How Gleevec transformed leukemia treatment. National Cancer Institute. April 11, 2018. Accessed November 10, 2025. https://www.cancer.gov/research/progress/discovery/gleevec#:~:text=NCI-supported%20research%20led%20to,evidence%20to%20support%20this%20hypothesis

2. Druker BJ, O’Brien SG, Cortes J, Radich J; Chronic myelogenous leukemia. Hematology Am Soc Hematol Educ Program. 2002 (1):111–135. doi:10.1182/asheducation-2002.1.111

3. Chronic myeloid leukemia (CML) research. Blood Cancer United. Accessed November 10, 2025. https://bloodcancerunited.org/research/blood-cancer-research-development-progress/leukemia/chronic-myeloid-leukemia-cml

4. Targeted therapy for cancer. National Cancer Institute. Updated May 31, 2022. Accessed November 11, 2025. https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies

5. Faiman B. The impact of federal funding cuts on research, practice, and patient care. J Adv Pract Oncol. 2025;16(4):124-125. doi:10.6004/jadpro.2025.16.4.1